2种方法检测非小细胞肺癌EGFR基因突变的比较  

Detection of EGFR mutations in non-small cell lung cancer tissues by two methods

作　　者：罗凯[1,2] 王倩[3] 刘季芳[1,2] 潘东晓[1,2] 薛兴阳[1,2] 傅文凡[1,2] 贺智敏[1,2] 

机构地区：[1]广州医学院肿瘤研究所 [2]广州医学院附属肿瘤医院,广东广州510095 [3]广州市中医医院病理科,广东广州510130

出　　处：《国际检验医学杂志》2013年第2期162-164,共3页International Journal of Laboratory Medicine

摘　　要：目的比较测序法和Taqman实时荧光PCR法检测表皮生长因子受体(EGFR)基因19、21外显子基因突变的一致性,为寻找适宜临床应用的EGFR基因突变检测方法提供实验依据。方法收集60例非小细胞肺癌患者肿瘤组织,应用测序法和Taqman实时荧光PCR法分别检测EGFR基因19、21外显子基因突变,比较两种方法的有效性。结果两法检测EGFR基因19、21外显子突变结果符合率分别为96.7%(58/60)和98.3%(59/60),差异无统计学意义(P>0.05)。结论 2种方法均可用于EGFR基因19、21外显子突变检测,测序法更适合指导临床分子靶向治疗。Objective To compare DNA sequencing and Taqman real-time PCR detecting EGFR exon 19 and 21 mutations in order to find a suitable clinical detection method of gene mutations.Methods To detect EGFR exon 19 and 21 mutations in 60 non-small cell lung cancer patients by DNA sequencing and Taqman real-time PCR and to analyze two methods＇ efficiency.Results There was no significant difference between two methods in detecting EGFR exon 19 and 21 mutations（P0.05） and the result coincidence rates of exon 19 and 21 mutations detection were 96.7%（58/60） and 98.3%（59/60）,respectively.Conclusion DNA sequencing and Taqman Real-time PCR all could be used for mutations detection of EGFR exon 19 and 21.DNA sequencing is more suitable for guiding the clinical molecular targeted therapy.

关 键 词：受体 表皮生长因子 基因测序 聚合酶链反应 

分 类 号：R734.2[医药卫生—肿瘤]